Please assess the completion status of the following clinical trial:

Trial Title: Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female aged ≥20 years~2. Maintenance of dual or triple antiplatelet therapy at least 12 ± 6 months after PCI with DES~3. No history of further clinical event after PCI with DES~4. Plan to change to antiplatelet monotherapy~5. Agreement to give written informed consent~Exclusion Criteria:~1. History of hypersensitivity to aspirin or clopidogrel~2. History of contraindication to aspirin or clopidogrel~3. Active pathologic bleeding, such as peptic ulcer, tumor bleeding or intracranial hemorrhage~4. History of major bleeding, BARC class ≥3, resulting in stop of antiplatelet agents within 3 months~5. Bleeding diathesis~6. Known coagulopathy or refusal of blood transfusion~7. Presence of non-cardiac comorbidity with life expectancy \&lt;2 years from randomization~8. Plan to surgery or intervention which needs to stop antiplatelet agents ≥3 months~9. Females with childbearing potential or breast-feeding~10. Conditions that may result in protocol non-compliance by the committees~11. Co-administration of contraindicated medications as follows: other P2Y 12 inhibitors (prasugrel or ticagrelor); anticoagulants (warfarin, new oral anticoagulants, or chronic therapy of heparin); cytochrome P450 2C19 inhibitors (fluoxetine, moclobemid or voriconazole); probenecid; high dose of methotrexate (≥15 mg/week); lithium~12. Refusal to give written informed consent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): Antiplatelet monotherapy : Clopidogrel 75mg P.O. daily
- Aspirin (Type: PLACEBO_COMPARATOR): Antiplatelet monotherapy : Aspirin 100\~200mg P.O. daily

Based on this trial design, predict the completion outcome and termination type (if applicable).